Prevalence

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study

Retrieved on: 
Monday, March 25, 2024
Prevalence, Exercise, Gastrointestinal bleeding, Risk, GI, Sale, Nonsteroidal anti-inflammatory drug, Running, Veterinary medicine, Motion, OA, Chronic pain, Quality of life, Osteoarthritis, Arthritis, Dog, PROM, Aspirin, Cartilage, Bioelectronics, FDA, Animal, BIEL, Ibuprofen, Audit

Forty-nine animals completed the study. No negative side effects were reported. Average subjective discomfort scores for the treatment group (N=26) were reduced from 4.26 to 2.31 (45%) compared to no improvement in the placebo group (N=23) over the study period. Average PROM scores increased by 5.51 (4.59--6.23) degrees relative to the placebo group. Ninety-six percent of the treatment group showed either increased PROM or improved behavioral changes or both compared to 4% for the placebo group. Most changes occurred within the first 8 days of treatment.

Key Points: 
  • The study was published online by Veterinary Medicine & Science, and can be viewed here: https://doi.org/10.1002/vms3.1408
    A randomized, blinded, placebo-controlled 14-day study of 60 dogs having prior veterinary-diagnosis OA in at least one limb joint.
  • BioElectronics’ Model 088 device was secured near the cervical region of the dog’s spine.
  • Osteoarthritis is the most common type of arthritis in dogs and is the most common source of chronic pain in older dogs.
  • Armed with these published results, BioElectronics Corporation will pursue appropriately qualified distribution partners to market and sell its unique pulsed shortwave device into the veterinary medicine market.

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

Retrieved on: 
Monday, March 25, 2024
Depression, Prevalence, Data analysis, MDD, COVID-19, Patient, Education, Ageing, Transcranial magnetic stimulation, TMS, DSM-IV codes, Quality of life, Adolescence, Safety, Marketing, STIM, FDA, Parent, Food, Pharmaceutical industry

NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.

Key Points: 
  • NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.
  • "The prevalence of depression in adolescents and young adults has been accelerating since the COVID-19 pandemic.
  • "NeuroStar’s TMS therapy now offers a promising first-line treatment for adolescents, backed by real-world data and impressive response rates consistent with response rates for adults.
  • This advancement has the potential to set a new treatment paradigm for how we address depression in our youth."

Hopebridge Gears Up for World Autism Month, Spreads Awareness of 1 in 36 Autism Prevalence

Retrieved on: 
Monday, March 25, 2024
Element, Speech, Social, Prevalence, Learning, Communication, Education, Research, Autism spectrum, Social media, Behavior, CDC, Spectrum, ASD, Residential care

Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, is preparing for an exciting month ahead: World Autism Month.

Key Points: 
  • Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, is preparing for an exciting month ahead: World Autism Month.
  • Hopebridge emphasizes to the public that this is a time to recognize and raise awareness about autism spectrum disorder (ASD) acceptance and inclusion.
  • To Hopebridge, the month of April is an opportunity to ignite change for children, families and the autism community as a whole.
  • "World Autism Month is a time to celebrate the diversity and resilience of individuals on the autism spectrum,” said Hopebridge founder, Kim Strunk.

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, American Heart Association, Administration, Conference call, Conference, Target, Obesity, Prevalence, CKD, Part, Patient, SGLT2, G&A, Pivotal, Insurance, Investment, Research and development, AHA, Therapy, EGFR, Senior management, Safety, Chronic kidney disease, Hypertension, Leptin, BMI, Aldosterone, Pharmaceutical industry

RADNOR, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the fourth quarter and full year ending December 31, 2023, and provided a corporate update.

Key Points: 
  • R&D expenses for the quarter ended December 31, 2023 were $23.7 million, compared to $7.8 million for the quarter ended December 31, 2022.
  • G&A expenses were $4.0 million for the quarter ended December 31, 2023, compared to $2.2 million for the quarter ended December 31, 2022.
  • Total other income, net was $3.3 million for the quarter ended December 31, 2023, compared to $0.9 million for the quarter ended December 31, 2022.
  • Net loss was $24.4 million for the quarter ended December 31, 2023, compared to $9.1 million for the quarter ended December 31, 2022.

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Ovarian cancer, Head, Uterine cancer, GSK, Patient, Dendreon, Commercial, Cancer, Bristol Myers Squibb, Neoplasm, Melanoma, TCR, Therapy, Research, MAGEA4, Sarcoma, GMP, Safety, Pharmacokinetics, Amgen, QC, CDMO, Development, Prevalence, Half-life, RECIST, Senior, FDA, Lung cancer, Administration, Conference, Entrepreneurship, Bank, Corr, Messenger, Protein, Pharmacology, Uveal melanoma, Pharmaceutical industry

“Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.

Key Points: 
  • “Immatics kicked off 2024 with a successful capital raise, providing significant financial runway and additional momentum to advance our ongoing clinical cell therapy and bispecific trials,” said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics.
  • For IMA203CD8 GEN2, Immatics cleared dose level 4a (DL4a, up to ~1.6x109 TCR-T cells) in December 2023, which is currently intended to be the target dose for further development.
  • A next data update for both Phase 1b cohorts with IMA203 GEN1 and IMA203CD8 GEN2 is planned for 2H 2024.
  • On September 11, 2023, Immatics announced a strategic multi-platform collaboration with Moderna, combining Immatics’ target and TCR platforms with Moderna’s cutting-edge mRNA technology.

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

Retrieved on: 
Wednesday, March 20, 2024
Tendinopathy, Artificiality, Health, Patient, Conditional sentence, History, Artificial intelligence, Lantern, Mantle cell lymphoma, OTCQX, Microsoft HoloLens, Context, Corporation, NEO, Microsoft, Automation, MCL, DHL, Splenic infarction, Diabetes, Risk, PALM, Radiology, Software, Treatment, UiPath, OTCQB, Strategic alliance, Prevalence, Disease, Microsoft Mesh, Hospital, Research, News, WELL, Student, TSX, MPH, Nursing, Machine learning, Diagnosis, TED (conference), OSCE, Growth, Cancer, Trust, Sarcoma, NHL, Appendicitis, Ecosystem, Probability, AIDX, Medical device

A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.
  • MarketsAndMarkets continued: “Based on component, the AI in medical diagnostics market is bifurcated into software, services, and hardware.
  • The software segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.
  • The hospitals segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.

Impressive $3.3M investment in Basic Mental Health Research

Retrieved on: 
Tuesday, March 19, 2024
Depression, Health, Basics, Mental health, Obesity, Prevalence, Drug discovery, University of Calgary, Insulin, Risk, Knowledge, Insulin resistance, The Honourable, Power Corporation of Canada, Research, Anxiety, University, Laboratory, Health Canada, Woman, Addiction, University of Toronto, Nursing

Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.

Key Points: 
  • Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.
  • The Basics of Better Mental Health Program funds basic research that will provide insight into the causes and onset of mental health conditions, explore the neuropathological changes and information-processing deficits that may eventually lead to new directions for treatments and interventions, and explore the role of sex and gender in mental health.
  • "Brain research plays a critical role in increasing our understanding of the causes and onset of mental health conditions,” says the Honourable Ya’ara Saks, Minister of Mental Health and Addictions.
  • “I am thrilled to support the work being done through the Basics of Better Mental Health Program – this work will support better mental health for all Canadians.”
    “The inclusion of sex-specific biological considerations is instrumental in understanding the biological roots of mental health conditions,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

Cover the Latest Developments in Allergy and Clinical Immunology at the EAACI Congress 2024 in Valencia, Spain

Retrieved on: 
Tuesday, March 19, 2024
Food, Conjunctivitis, Prevalence, Atopic dermatitis, Data science, Incidence, Patient, Research, Science, Congress, EAACI, Asthma, Physician, Health care, Cochineal

VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI), with a membership of over 16,000 from 125 countries, annually orchestrates its congress to unveil the latest research and innovative advancements in allergy and clinical immunology. We are thrilled to extend a warm invitation to you for the upcoming EAACI Congress 2024, scheduled to take place in Valencia from May 31st to June 3rd, 2024.In a bid to provide you with an immersive experience, we will offer you a dedicated press area where you can schedule interviews with leading physicians and researchers in the field.

Key Points: 
  • VALENCIA, Spain, March 19, 2024 (GLOBE NEWSWIRE) -- The European Academy of Allergy and Clinical Immunology (EAACI), with a membership of over 16,000 from 125 countries, annually orchestrates its congress to unveil the latest research and innovative advancements in allergy and clinical immunology.
  • We are thrilled to extend a warm invitation to you for the upcoming EAACI Congress 2024, scheduled to take place in Valencia from May 31st to June 3rd, 2024.
  • Our venue, Feria de Valencia , is a prestigious convention and exhibition centre known for its modernity and versatility.
  • The Scientific Programme will encompass the entire spectrum of Allergy and Clinical Immunology.

BrainsWay Broadens Partnership with Katie’s Way Plus Through Order of an Additional 18 Deep TMS™ Systems

Retrieved on: 
Monday, March 18, 2024
Depression, Deep, Transcranial magnetic stimulation, Brainsway, Prevalence, Veteran, Mental, Memory, Partnership, TMS, Acquisition, Hope, DSM-IV codes, Military personnel, Marketing, Suicide, Nursing

Katie’s Way Plus will now grow to an extensive network of approximately 40 Deep TMS systems.

Key Points: 
  • Katie’s Way Plus will now grow to an extensive network of approximately 40 Deep TMS systems.
  • “We are delighted to continue supporting Katie's Way Plus in its pivotal mission of delivering specialized care to U.S. service members, veterans, and their families,” said Chris Boyer, BrainsWay’s Vice President of Marketing.
  • “The efficacy demonstrated by BrainsWay's advanced Deep TMS technology in the treatment of depression is transformational.
  • In one study conducted across 27 states, it was found that the suicide rate among veterans is 50% higher than non-veterans1.

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Research, Certification, Quarter, Prevalence, Teva Pharmaceuticals, Gastrointestinal disease, Partnership, ACG, Metoclopramide, Patient, Pharmacy, Gastroparesis, Health care, Holocene, Prescription, Orange Book, Marketing, Gastroenterology, Woman, DDW, PBM, Hospital, Pharmaceutical industry

SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recent corporate developments.

Key Points: 
  • Our commercial team’s dedicated efforts yielded a 107% increase in year-over-year revenue,” stated Dave Gonyer, R.Ph., CEO of Evoke Pharma.
  • Research and development expenses totaled approximately $23,000 for the fourth quarter of 2023 compared with $27,000 for the fourth quarter of 2022.
  • For the fourth quarter of 2023 selling, general and administrative (SG&A) expenses were approximately $3.5 million compared with $2.3 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were approximately $3.6 million compared with $2.3 million for the same period of 2022.